[at noodls] – — Results from Phase 3 VALENCE Study Confirm Efficacy and Safety of All-Oral Sofosbuvir-Based Regimen in Hepatitis C Patients with Genotype 3 Infection — WASHINGTON–(BUSINESS WIRE)–Nov. 2, 2013– Gilead …
Read more on this.
Gilead Sciences Inc. … [visit site to read more]
Similar posts:- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review
- Oil and Natural Gas Stocks: This small U.S.-based energy company has it all
- Boeing’s Double Top: Will the company continue to soar?